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Abstract: Background and Aims: It is not known whether inflammatory bowel disease (IBD)
enhances the risk of Parkinson’s disease (PD) or whether PD diagnosis is the result of increased health
care use. We determined the risk of developing PD among patients with IBD in terms of health care
and medication use. Methods: A nationwide population-based study was conducted using claims
data from the Korean National Health care Insurance service. From 2010 to 2013, patients with Crohn’s
disease (CD) and ulcerative colitis (UC) were identified through both International Classification of
Disease, Tenth Revision (ICD-10) and national rare intractable disease (RID) registration program
codes. We compared 38,861 IBD patients with age and sex-matched non-IBD individuals at a ratio
of 1:3. Patients with newly diagnosed PD were identified through both ICD-10 and RID codes.
Results: The incidence of PD among patients with IBD was 49 per 100,000 person-years. The risk of
developing PD in patients with IBD was significantly higher than controls even after adjustment for
health care use (adjusted hazard ratio (aHR), 1.87; P < 0.001). Compared to controls, the risk of PD
was significantly higher in patients with CD (aHR, 2.23; P = 0.023) and UC (aHR, 1.85; P < 0.001).
Corticosteroid use showed a preventive effect on developing PD in patients with CD (aHR 0.08;
P < 0.001), but not UC (aHR, 0.75; P = 0.213). Among 2110 patients receiving anti-tumor necrosis
factor (anti-TNF), none of the treated patients experienced PD during 9950 person-years. Conclusion:
Patients with IBD are at an increased risk of PD, regardless of health care use. Corticosteroid and
anti-TNF use may prevent PD in patients with IBD.
Keywords: Claims data; Crohn’s disease; inflammatory bowel disease; Parkinson’s disease;
ulcerative colitis
1. Introduction
Parkinson’s disease (PD) is the second most common neurodegenerative disorder and is
characterized by the premature loss of dopaminergic neurons in the substantia nigra and abnormal
aggregates of theα-synuclein protein, affecting 1% of people over 60 years of age. The disease progresses
slowly and causes motor dysfunction, such as bradykinesia, resting tremor, rigidity and postural
instability, and non-motor features, such as hyposmia, sleep disturbances, depression, constipation,
and other dysautonomic symptoms [1]. Most epidemiological studies have shown that PD increases
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mortality hazard ratios by 1.5–2.7 times compared to the general population [2]. In addition, 25–40% of
patients with PD eventually develop dementia, which also contributes to reduced life expectancy [3,4].
Although numerous risk factors, including oxidative stress, environmental toxins, and some genetic
mutations, are known to be associated with PD, the pathophysiology of neurodegeneration in PD
has not been fully elucidated [5,6]. Recently, accumulating evidence has demonstrated that systemic
inflammation is closely linked to the pathogenesis of PD, which suggests that chronic inflammation
in peripheral organs may contribute to neurodegeneration in PD by altering blood–brain barrier
permeability [7,8]. Peripheral cytokines, such as interleukin (IL)-6, tumor necrosis factor (TNF), IL-1β,
IL-2, IL-10 and C-reactive protein, are increased in patients with PD [9,10]. As such, human studies have
shown that a variety of chronic inflammatory diseases including autoimmune rheumatoid arthritis [11],
Sjögren syndrome [12], and periodontal inflammatory disease [13] increase the risk of PD development.
Inflammatory bowel disease (IBD), which includes Crohn’s disease (CD) and ulcerative colitis (UC),
is a chronic, relapsing inflammatory disease of the intestine [14]. Dynamic interactions between genetic
predisposition, environmental, and immunological factors contribute to the pathogenesis of IBD [15–17].
The dysbiosis of gut microbiota and destruction of the epithelial barrier affect the initiation and
perpetuation of chronic inflammation in the gut [18,19]. In addition, psycho-neuro-endocrine-immune
modulation through the brain–gut axis may play an important role in the pathogenesis of IBD [20].
Growing awareness of communication between the intestinal environment and central nervous system
activity through the brain–gut axis has led to the hypothesis that chronic intestinal inflammation may
result in neurodegeneration in PD [21]. It has been confirmed that IBD and PD share common genetic
risk profiles, such as NOD2, LRRK2 and MAPT genes [22–26].
Several recent epidemiologic studies [27–33] have been conducted to determine whether IBD
increases the risk of PD based on common biologic and genetic mechanisms described in the
pathogenesis of IBD and PD. However, there is still controversy regarding the risk of PD in patients
with IBD because increased health care use following a diagnosis of IBD is likely to act as a surveillance
bias in interpreting a causal relationship between IBD and the risk of PD [34,35]. In addition, whether
therapeutic agents for treating IBD lower the risk of developing PD remains unknown. The aim of this
nationwide population-based study was to determine the risk of developing PD among patients with
IBD compared to the general population in terms of health care use and concomitant medication for
treating IBD.
2. Material and Methods
2.1. Data Source
We conducted a retrospective population-based cohort study using a database provided by the
National Health Insurance Service (NHIS) in South Korea. The NHIS is a single payment program
established by the Korean government. Approximately 52 million residents in Korea are obliged by law
to enroll in NHIS, and the health care provider must submit the required claims data to receive medical
reimbursement. Therefore, all relevant data are accumulated in the NHIS database [36]. The NHIS
database contains information on personal demographics, hospitalization and outpatient medical use,
medications, medical procedures and diagnoses identified by International Classification of Disease,
Tenth Revision (ICD-10) codes. NHIS has established a rare intractable disease (RID) enrollment
program to strengthen medical reimbursement by reducing the economic burden of treating RIDs, such
as PD and IBD. To enroll patients with RIDs in this program, qualified physicians have to evaluate
whether the diseases meet the diagnostic criteria for each RID. When registered in the RID program, a
special diagnostic code (V code) is assigned in addition to the ICD-10 code. For patients with IBD, the
V code is provided only if they meet specific comprehensive diagnostic criteria, including imaging,
histologic, clinical and endoscopic findings. This study protocol was exempt from Seoul National
University Hospital Institutional Review Board (H-1703-107-840).
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2.2. Study Population
In this study, we included 38,861 patients with IBD who enrolled with both ICD-10 and V codes
from January 2010 to December 2013 in the NHIS database. CD patients were identified using both
ICD-10 K50 and V130 codes, and UC patients were identified using both ICD-10 K51 and V131 codes.
As described in previous studies [37–42], the diagnostic accuracy of IBD using both the V code and
ICD-10 codes has been validated. In brief, the diagnostic sensitivity of CD and UC was found to be 94.5
and 96.4%, respectively. In addition, the IBD cohort was divided into the incident IBD group, which
was newly registered with both ICD-10 and V codes from January 2010 to December 2013 (patients
without a history of IBD from January 2005 to inclusion date), and prevalent IBD group, for which the
IBD code was registered between 2005 and inclusion date, with reimbursement for IBD between 2010
and 2013. A total of 116,583 age- and sex-matched individuals without IBD were randomly selected as
non-IBD controls at a 1:3 ratio. Individuals with other immune-mediated diseases were not excluded
from the non-IBD controls.
2.3. Data Collection
In addition to demographics (age, sex, place of residence, and income level), information about the
drugs used to treat IBD, including corticosteroids, immunomodulators (azathioprine/6-mercaptopurine
and methotrexate), and anti-TNF agents (infliximab, adalimumab and golimumab), in both IBD and
non-IBD groups was collected. Medication use was defined as a prescription issued within 1 year
following IBD diagnosis. We also collected information on comorbidities, including hypertension
(defined as ICD-10 codes (I10–13, I15) with antihypertensive agents), diabetes mellitus (DM; defined
as ICD-10 codes (E11–14) with antihyperglycemic agents), dyslipidemia (defined as ICD-10 code
(E78) with antihyperlipidemic agents), depression (defined as ICD-10 code (F32–34)), myocardial
infarction (defined as ICD-10 code (I21–22) with hospitalization), stroke (defined as ICD-10 code
(I63–64) with hospitalization and brain imaging with computed tomography or magnetic resonance
imaging), and ischemic heart disease (defined as ICD-10 code (I20–25) with hospitalization), as
described previously [39,42–44]. Health care use was defined as a total number of inpatient and/or
outpatient visits within 1 year after IBD diagnosis or the inclusion date.
2.4. Study Endpoint
PD was defined as a patient assigned both ICD-10 (G20) and V codes (V124), as described in a
previous study [45]. The ICD-10 G21 code (secondary parkinsonism) was not used to detect individuals
with idiopathic PD. In general, PD is diagnosed based on the clinical characteristics, and the United
Kingdom (UK) Parkinson’s Disease Society Brain Bank criteria is used in practice [5]. The criteria for the
V124 code are identical to the UK Parkinson’s Disease Society Brain Bank diagnostic criteria as follows:
(1) The diagnostic criteria for PD include mild or worse bradykinesia and at least 1 of the following:
muscular rigidity, rest tremor and postural instability. (2) The exclusion criteria for PD are a history
of strokes, head injury, definite encephalitis, drug adverse events and hypoxia. (3) The supportive
prospective positive criteria for PD include 3 or more of the following conditions in combination
with those from (1), which are required for the diagnosis of definite PD: unilateral onset, presence of
rest tremor, progressive disorder, persistent asymmetry affecting the side of onset the most, excellent
response to levodopa, severe levodopa-induced chorea, levodopa response for 5 years or more and
clinical course of 10 years or more [45]. The IBD cohort and non-IBD controls were followed up until
the occurrence of PD or December 2015. The primary endpoint was newly developed PD during the
follow-up period.
2.5. Statistical Analysis
Baseline demographics, comorbidities and medications in the IBD cohort and non-IBD control
were compared. Differences between the two groups were assessed with independent t-tests for
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continuous variables and χ2 tests for categorical variables. The incidence of PD was calculated as the
number of events per 100,000 person-years in each group. Cox proportional hazard regression models
were used to show the effect of IBD on the risk of PD. Results were expressed as hazard ratio (HR)
and 95% confidence interval (CI). In multivariable models, age, sex, place of residence, income level,
comorbidities as well as health care use were adjusted. The cumulative incidence of PD in the IBD
and non-IBD groups was compared using the Kaplan–Meier method and log-rank test. A P Value <
0.05 was considered statistically significant. R program version 3.4.3 (The R Foundation for Statistical
Computing, Vienna, Austria, http://www.R-project.org) and SAS version 9.2 (SAS Institute Inc., Cary,
NC, USA) for Windows were used for statistical analysis.
3. Results
3.1. Baseline Characteristics of the Study Population
From January 2010 to December 2013, a total of 38,861 and 116,583 individuals were enrolled
in the IBD and non-IBD groups, respectively, matched by age and sex. The mean age was 39.9
years and 61.2% were male. The study participants aged 60 and older were 14.0, 5.6, and 18.1% in
IBD, CD, and UC groups, respectively. The IBD cohort was significantly associated with a lower
proportion of rural residents (P < 0.001) and income levels below 20% (P < 0.001) compared to non-IBD
control. The prevalence of DM (P < 0.001), hypertension (P < 0.001), and dyslipidemia (P = 0.029)
was significantly lower in the IBD cohort compared to controls. In contrast, myocardial infarction
(P < 0.001), stroke (P = 0.023), ischemic heart disease (P < 0.001), and depression (P < 0.001) in the
IBD cohorts was significantly more prevalent than in the non-IBD controls. The frequency of health
care use was significantly higher in the IBD cohort compared to controls (20.0 visits/year vs. 11.9
visits/year; P < 0.001). Among the medications used to treat IBD, corticosteroids, immunomodulators
and anti-TNF agents were prescribed in 57.4, 26.8 and 5.4% of the IBD cohort, respectively, and were
used more frequently compared to non-IBD controls (Table 1).
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Table 1. Baseline characteristics of the study population.
IBD CD UC
Non-IBD
Control (n =
116,583)
IBD Cohort
(n = 38,861) P Value
Non-CD
Control (n =
37,893)
CD Cohort (n
= 12,631) P Value
Non-UC
Control (n =
78,690)
UC Cohort (n
= 26,230) P Value
Age, years * 39.91 ± 16.62 39.91 ± 16.62 - 30.74 ± 14.56 30.74 ± 14.56 - 44.33 ± 15.72 44.33 ± 15.72 -
≥60 ‡ 16,335 (14.0) 5445 (14.0) - 2130 (5.6) 710 (5.6) - 14,205 (18.1) 4735 (18.1) -
Male gender ‡ 71,292 (61.2) 23,764 (61.2) - 26,580 (70.1) 8860 (70.1) - 44,712 (56.8) 14,904 (56.8) -
Rural residence ‡ 62,113 (53.3) 19,328 (49.7) <0.001 20,117 (53.1) 6186 (49.0) <0.001 41,996 (53.4) 13,142 (50.1) <0.001
Lowest income 20% †,‡ 27,195 (23.3) 7687 (19.8) <0.001 8785 (23.2) 2668 (21.1) <0.001 18,410 (23.4) 5019 (19.1) <0.001
Comorbidities
DM ‡ 5786 (5.0) 1610 (4.1) <0.001 867 (2.3) 280 (2.2) 0.642 4919 (6.3) 1330 (5.1) <0.001
Hypertension ‡ 14,911 (12.8) 4503 (11.6) <0.001 2312 (6.1) 684 (5.4) 0.005 12,599 (16.0) 3819 (14.6) <0.001
Dyslipidemia ‡ 8621 (7.4) 2744 (7.1) 0.029 1388 (3.7) 389 (3.1) 0.002 7233 (9.2) 2355 (9.0) 0.299
Depression ‡ 3535 (3.0) 2336 (6.0) <0.001 760 (2.0) 690 (5.5) <0.001 2775 (3.5) 1646 (6.3) <0.001
Ischemic heart disease ‡ 4028(3.5) 1764 (4.6) <0.001 631 (1.7) 392 (3.1) <0.001 3397 (4.3) 1372 (5.2) <0.001
History of myocardial infarction ‡ 458 (0.4) 235 (0.6) < 0.001 73 (0.2) 68 (0.5) <0.001 385 (0.5) 167 (0.6) 0.004
History of stroke ‡ 1752 (1.5) 648 (1.8) 0.023 241 (0.6) 129 (1.0) <0.001 1,511 (1.9) 519 (2.0) 0.552
Medications for IBD
Corticosteroids ‡ 37,450 (32.1) 22,321 (57.4) < 0.001 10,793 (28.5) 7417 (58.7) <0.001 26,657 (33.9) 14,904 (56.8) <0.001
Immunomodulators ‡ 373 (0.3) 10,405 (26.8) < 0.001 92 (0.2) 7008 (55.5) <0.001 281 (0.4) 3397 (13.0) <0.001
Anti-TNF ‡ 28 (0.0) 2110 (5.4) < 0.001 11 (0.0) 1665 (13.2) <0.001 17 (0.0) 445 (1.7) <0.001
Follow-up period, years * 4.88 ± 1.27 4.87 ± 1.29 0.201 4.90 ± 1.27 4.86 ± 1.31 0.005 4.88 ± 1.28 4.88 ± 1.28 0.704
Health care visits * 11.86 ± 17.84 20.0 ± 20.7 < 0.001 8.43 ± 13.73 17.56 ± 18.23 <0.001 13.51 ± 19.3 21.17 ± 21.69 <0.001
CD, Crohn’s disease; DM, diabetic mellitus; IBD, inflammatory bowel disease; TNF, tumor necrosis factor; UC, ulcerative colitis. * Mean ± SD. † Defined as patients whose income was in
the bottom 20%. ‡ Number (%).
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3.2. Incidence and Risk of Parkinson’s Disease in Patients with Inflammatory Bowel Disease
Of the 38,861 patients in the IBD cohort, 16,620 were in the incident IBD group and 22,241 were in
the prevalent IBD group. During a mean follow-up of 4.9 years, 92 patients (0.24%) in the IBD cohort
and 134 patients (0.11%) in the non-IBD control group developed PD. The mean age at diagnosis of PD
was significantly lower in the IBD patients than in the non-IBD controls (60.9 vs. 64.1 years; P = 0.036).
The mean age at diagnosis of PD in those with CD was significantly lower compared to the controls
(53.7 vs. 64.9 years; P = 0.014), but there was no significant difference in the mean age at diagnosis of
PD between UC and control groups (62.3 vs. 63.9 years; P = 0.305). The cumulative incidence of PD in
patients with CD and UC was significantly higher compared to the control groups (Figure 1A,B).
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Figure 1. Kaplan–Meier plots show the cumulative incidence of Parkinson’s disease in patients with
inflammatory bowel disease. (A) Patients with Crohn’s disease; (B) Patients with ulcerative colitis.
Abbreviations: CD, Crohn’s disease; PD, Parkinson’s disease; UC, ulcerative colitis.
The incidence and i f PD in the IBD cohort was significantly hig er than in non-IBD
controls after adjustment for age, sex, place of residence, income l l, c r i iti s including DM,
hypertension, dyslipidemia, depr ssion, stroke, myocardi l infarction and ischemic heart disease, and
number of h alth care visits (49 vs. 2 per 100,000 person-y ars; adjusted HR, 1.87; 95% CI, 1.43–2.44; P
< 0.001 in Model 3) (Table 2 .
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Table 2. Incidence and risk of Parkinson’s disease in patients with inflammatory bowel disease.
Total No. PD Cases Person-Years(y)
PD Incidence
(/100,000
Person-Years)
Age at PD
Diagnosis,
Years *
Model 1 † HR
(95% CI)
P Value Model 2
‡ HR
(95% CI)
P Value Model 3
§ HR
(95% CI)
P Value
Total IBD <0.001 <0.001 <0.001
Control 116,583 134 569,360 24 64.1 ± 10.2 1 (Ref.) 1 (Ref.) 1 (Ref.)
Case 38,861 92 189,415 49 60.9 ± 12.1 2.07 (1.59–2.70) 1.95 (1.49–2.54) 1.87 (1.43–2.44)
IBD subgroup
Incident 16,620 25 65,692 38 61.8 ± 11.7 1.93 (1.26–2.96) 0.003 1.65 (1.07–2.55) 0.023 1.58 (1.02–2.44) 0.039
Prevalent 22,241 67 123,722 54 60.6 ± 12.3 2.13 (1.59–2.86) <0.001 2.08 (1.55–2.8) <0.001 2.00 (1.49–2.70) <0.001
Total CD 0.008 0.012 0.023
Control 37,893 19 185,637 10 64.9 ± 8.2 1 (Ref.) 1 (Ref.) 1 (Ref.)
Case 12,631 15 61,416 24 53.7 ± 16.3 2.52 (1.28–4.95) 2.44 (1.22–4.86) 2.23 (1.12–4.45)
CD subgroup
Incident 5607 4 21,928 18 57.8 ± 16.2 1.71 (0.58–5.05) 0.332 1.52 (0.51–4.55) 0.457 1.36 (0.45–4.07) 0.587
Prevalent 7024 11 39,488 28 52.3 ± 16.9 3.05 (1.44–6.43) 0.004 3.12 (1.46–6.69) 0.004 2.91 (1.36–6.24) 0.006
Total UC <0.001 <0.001 <0.001
Control 78,690 115 383,722 30 63.9 ± 10.5 1 (Ref.) 1 (Ref.) 1 (Ref.)
Case 26,230 77 127,998 60 62.3 ± 10.6 2.00 (1.50–2.67) 1.92 (1.43–2.56) 1.85 (1.38–2.48)
UC subgroup
Incident 11,013 21 43,765 48 62.6 ± 11.0 1.97 (1.23–3.15) 0.005 1.75 (1.09–2.8) 0.020 1.68 (1.05–2.69) 0.031
Prevalent 15,217 56 84,234 66 62.2 ± 10.6 2.01 (1.46–2.77) <0.001 1.99 (1.44–2.75) <0.001 1.93 (1.40–2.67) <0.001
CD, Crohn’s disease; CI, confidence interval; HR, hazard ratio; IBD, inflammatory bowel disease; No, number; PD, Parkinson’s disease; Ref., reference; UC, ulcerative colitis. * Mean ± SD.
† Model 1: adjusted for age, sex. ‡ Model 2: adjusted for model 1 + place of residence, income level, diabetes mellitus, hypertension, dyslipidemia, depression, ischemic heart disease,
history of myocardial infarction, and stroke. § Model 3: adjusted for model 2 + health care visits.
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The incidence and risk of PD was significantly higher than in non-IBD controls when the IBD
cohort was divided into the incident IBD group (38 vs. 24 per 100,000 person-years; adjusted HR,
1.58; 95% CI, 1.02–2.44; P = 0.039 in Model 3) and the prevalent IBD group (54 vs. 24 per 100,000
person-years; adjusted HR, 2.00; 95% CI, 1.49–2.70; P < 0.001 in Model 3). In patients with CD,
the incidence and risk of PD was significantly higher compared to controls (24 vs. 10 per 100,000
person-years; adjusted HR, 2.23; 95% CI, 1.12–4.45; P = 0.023 in Model 3). Among patients in the
prevalent CD groups, the incidence and risk of PD was also significantly higher compared to controls
(incident CD group: adjusted HR, 1.36; 95% CI, 0.45–4.07; P = 0.587; prevalent CD group: adjusted HR,
2.91; 95% CI, 1.36–6.24; P = 0.006 in Model 3). In patients with UC, the incidence and risk of PD was
also significantly higher compared to controls (60 vs. 30 per 100,000 person-years; adjusted HR, 1.85;
95% CI, 1.38–2.48; P < 0.001 in Model 3). Among patients in both incident and prevalent UC groups,
the risk of PD was also significantly higher compared to controls (incident UC group: adjusted HR,
1.68; 95% CI, 1.05–2.69; P = 0.031; prevalent UC group: adjusted HR, 1.93; 95% CI, 1.40–2.67; P < 0.001
in Model 3).
When the comparative risks of PD in the study population were stratified by age at 60, IBD
patients had significantly increased risk of PD compared to controls, regardless of age (aged <60 years:
adjusted HR, 2.63; 95% CI, 1.57–4.41; P < 0.001 in Table S2; aged ≥60 years: adjusted HR, 1.63; 95% CI,
1.19–2.24; P = 0.003 in Table S3). However, there was no statistically significant difference in the risk of
PD between CD and control groups among individuals aged ≥60 years (Table S3).
3.3. Incidence and Risk of Parkinson’s Disease According to Medication Use
The incidence and risk of PD among CD patients, but not UC patients, who were treated with
corticosteroids was significantly lower than individuals who were not treated with corticosteroids (11
vs. 41 per 100,000 person-years; adjusted HR 0.08; 95% CI, 0.02–0.33; P < 0.001 in Model 2) (Table 3).
In terms of immunomodulator use, there was no significant difference in the incidence of PD among
patients with CD and UC. Of the 2110 patients who received anti-TNF agents, no patient experienced
PD during 9950 person-years (Table 3). In non-IBD controls, there was no significant difference in the
risk of PD according to medication use (Table 3).
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Table 3. Incidence and risk of Parkinson’s disease in patients with inflammatory bowel disease and non-inflammatory bowel disease controls according to medication.
Total No. PD Cases Person-Years(y)
PD Incidence (/100,000
Person-Years)
Model 1 * HR
(95% CI) P Value
Model 2 † HR
(95% CI)
P Value
CD
Corticosteroids 0.006 <0.001
No 5214 11 26,582 41 1 (Ref.) 1 (Ref.)
Yes 7417 4 34,834 11 0.19 (0.06–0.63) 0.08 (0.02–0.33)
Immunomodulators 0.193 0.227
No 5623 13 27,465 47 1 (Ref.) 1 (Ref.)
Yes 7008 2 33,951 6 0.35 (0.07–1.67) 0.38 (0.08–1.83)
Anti-TNF - -
No 10,966 15 53,347 28 1 (Ref.) 1 (Ref.)
Yes 1665 0 8069 0 - -
UC
Corticosteroids 0.386 0.213
No 11,326 35 56,378 62 1 (Ref.) 1 (Ref.)
Yes 14,904 42 71,621 59 0.82 (0.52–1.29) 0.75 (0.47–1.18)
Immunomodulators 0.541 0.521
No 22,833 71 111,139 64 1 (Ref.) 1 (Ref.)
Yes 3397 6 16,860 36 0.77 (0.33–1.78) 0.76 (0.33–1.76)
Anti-TNF - -
No 25,785 77 126,117 61 1 (Ref.) 1 (Ref.)
Yes 445 0 1881 0 - -
Non-IBD controls
Corticosteroids 0.353 0.585
No 79,133 73 388,691 19 1 (Ref.) 1 (Ref.)
Yes 37,450 61 180,669 34 1.18 (0.83–1.66) 1.10 (0.78–1.57)
Immunomodulators 0.108 0.116
No 116,210 132 567,574 23 1 (Ref.) 1 (Ref.)
Yes 373 2 1786 112 3.16 (0.78–12.84) 3.08 (0.76–12.52)
Anti-TNF -
No 116,555 134 569,235 24 1 (Ref.) 1 (Ref.)
Yes 28 0 125 0 - -
CI, confidence interval; CD, Crohn’s disease; HR, hazard ratio; IBD, inflammatory bowel disease; No, number; PD, Parkinson’s disease; Ref., reference; TNF, tumor necrosis factor; UC,
ulcerative colitis. * Model 1: adjusted for age, sex, place of residence, income level, diabetes mellitus, hypertension, dyslipidemia, depression, myocardial infarction, stroke, and ischemic
heart disease. † Model 2: adjusted for model 1 + health care visits.
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3.4. Subgroup Analysis
In this subgroup analysis, we evaluated differences in the risk of PD according to age, sex, and
comorbidities of patients with CD and UC after adjustment for age, sex, place of residence, income level,
comorbidities including DM, hypertension, dyslipidemia, depression, stroke, myocardial infarction
and ischemic heart disease. The impact of CD on developing PD was more prominent in patients less
than 60 years of age (adjusted HR, 7.70 vs. 1.02; interaction P value 0.012) and without hypertension
(adjusted HR, 4.58 vs. 1.01; interaction P value 0.030) (Figure 2A). In contrast, there was no significant
difference in the risk of PD according to the subgroup consisting of patients with UC (Figure 2B).
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4. Discussion
In this nationwide population-based study of approximately 160,000 Korean individuals, including
39,000 patients with IBD during a mean follow-up of 5 years, we demonstrated that patients with IBD
were 1.9 times significantly more likely to develop PD compared to non-IBD age- and sex-matched
controls, even after adjustment for health care visits and comorbidities. Of the IBD subtypes, CD and
UC patients were at 2.2- and 1.9-times higher risk for PD than controls, respectively.
In a literature review, five retrospective studies compared the risks of developing PD between IBD
and non-IBD groups (Table S1) [28–30,32,33,46]. In a case-control study from the United States [29],
PD was inversely associated with both CD and UC compared to non-PD controls after adjustment for
health care use, but only patients with PD over 65 years were included. In contrast, in a US cohort
study [33], the risk of PD was significantly higher in CD and UC patients compared to controls. In a
Taiwanese cohort study [32], the risk of PD was also 40% significantly higher in CD, but not UC,
compared to controls. However, both studies did not consider surveillance bias effects on the risk of
PD in IBD patients. Recently, a Swedish cohort study [30] reported that the risk of PD was 1.3 times
higher in UC compared to controls, but the increased risk of PD was not significant after adjustment
for health care visits. These findings have led to debates over whether IBD patients are exposed to
an increased risk of PD because IBD leads to increased health care uses. In contrast, a Danish cohort
study [28] showed a 22% increased risk of PD in IBD, which was also significant after adjustment for
number of health care visits (HR, 1.49; 95% CI, 1.34–1.66) [46].
In the present study, the increased risks of developing PD among IBD patients compared to
controls were statistically significant even after adjustment for health care visits, which is consistent
with the results of the Danish study [28,46]. The risks of developing PD among IBD patients were the
highest compared to all previous epidemiologic studies, even after adjustment for health care visits.
It should be noted that the mean age of the study population was 45 years or over in the other studies.
Aging is a crucial risk factor for developing PD [47]. Older mean age at the baseline is related to higher
risks of developing PD in the non-IBD controls. In this study, the mean age of the study population
was 40 years, and 92% of the subjects were under the age of 45. In addition, the comparative risk of
developing PD in patients with CD compared to controls was significant only among individuals
younger than 60 years of age. In terms of UC, the comparative risks for PD were significant compared
to controls regardless of age subgroups, but the adjusted HR decreased more in individuals greater
than or equal to 60 years of age than in those less than 60. Considering the confounding effect of age on
the occurrence of PD, IBD itself is an independent risk factor for developing PD. Moreover, it should
be noted that the age at diagnosis of PD in the IBD patients was significantly lower compared to the
controls. Especially, the comorbid PD was diagnosed before the age of 60 in most CD patients. Given
that IBD is a chronic inflammatory disorder occurring most commonly during adolescence and young
adulthood, physicians should be aware of the potential risk for PD in patients with IBD.
Recent evidence has shown that inflammation plays a crucial role in neuro-degenerative processes
of PD [48,49]. Active peripheral inflammation as well as deregulation of the inflammatory pathway
due to genetic vulnerability contributes to the initiation and progression of PD. In this study, steroid
therapy reduced the risk of developing PD by 92% among CD patients. Synthetic glucocorticoids act
as potent anti-inflammatory drugs, and previous studies have reported that dexamethasone plays a
neuroprotective role in animal PD models [50–52]. Moreover, there were no occurrences of PD among
2110 patients with IBD who received anti-TNF agents during approximately 10,000 person-years.
This is consistent with the results of previous studies on the preventive effects of anti-TNF agents
on development of PD [30,33]. TNF-α levels were increased in the substantia nigra and striatum of
the 6-hydroxydopamine-injected area of hemiparkinsonian rats [53]. The expression levels of TNF-α
and TNF-α receptor R1 were also enhanced in the nigrostriatal dopamine regions and ventricular
cerebrospinal fluid of patients with PD, which may be responsible for degeneration of dopaminergic
neurons in the substantia nigra pars compacta and loss of nerve terminals with dopamine deficiency in
the striatum, leading to development of PD [53]. TNF-α contributes to neuroinflammation on passing
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through the blood–brain barrier [8,54,55]. Anti-TNF agents are blocked by the blood–brain barrier,
but their effects on peripheral inflammation are likely to reduce neuroinflammation and the risk of
PD development. A previous study reported that peripheral TNF-α modulates amyloid pathology
by regulating blood-derived immune cells trafficking in a transgenic mouse model of Alzheimer’s
disease [56]. Recently, a prospective cohort study demonstrated that anti-TNF agents shifted the
diversity of gut microbiota in patients with IBD toward that of healthy individuals [57], suggesting
that anti-TNF agents might prevent neuroinflammation via modulating the gut microbiota in the
pathogenesis of neurodegenerative diseases.
There are some limitations to this study due to its retrospective design. First, we could
not determine the risk of developing PD in IBD based on disease severity from the claims data.
Interestingly, IBD patients receiving steroid or anti-TNF agents who may have had severe inflammatory
disease showed a significantly reduced risk of developing PD compared to those with mild disease.
This suggests that the impacts of steroids and anti-TNF agents outweigh the effects of intestinal
inflammation on the occurrence of PD among IBD patients. Second, the risks of developing PD in
IBD could not be adjusted for some potential confounding factors, such as lifestyle or personal health
behaviors, including tobacco smoking, coffee drinking, and alcohol consumption [5]. The patterns of
personal behavior might be different between IBD and non-IBD individuals. Third, the impacts of
genetic risk profiles such as NOD2, LRRK2 and MAPT on PD development in IBD could also not be
evaluated due to the study design and data availability. Fourth, how alterations in gut microbiota
composition influence the initiation of neurodegeneration in PD could not be evaluated. A shift
in gut microbiota composition together with the impacts of medications, lifestyle, diet and aging
may play a crucial role in the pathogenesis of PD by facilitating the ascending neurodegenerative
spread of α-synuclein aggregates from the enteric nervous system to the brain [58]. Braak H.
hypothesized that the pathological α-synuclein spreads via the vagus nerve to the brain leading to
the development of PD [59,60], which has been recently demonstrated in a mouse model of PD [61].
Colonic inflammation in marmosets was related to the pathologic phosphorylation of α-synuclein in
the colonic myenteric ganglia, which suggests that colitis may trigger the neurodegenerative spread
of pathologic α-synuclein [62]. Further investigations are needed to determine how changes in the
gut microenvironment contribute to the neurodegenerative pathway in human. An understanding
of the attributes of gut microenvironment changes in PD may lead to targeted prevention aimed at
modulating the gut microbiota. Fifth, we could not assess the risk of PD among IBD patients based on
the treatment response against IBD because the medications for IBD were defined as prescription-only
medications within 1 year following the diagnosis, taking into account a relatively short follow-up
period. Finally, the mean follow-up period of approximately 5 years may be short to fully evaluate the
significantly increased risks of PD in IBD patients, especially in incident CD patients, who showed
the lowest number of PD development during the shortest observed period (only four cases per
22,000 person-years) among all subgroups. Further long-term observational studies are required to
elucidate the cumulative risks of the neurodegenerative disease, mostly involving the elderly, among
IBD patients after diagnosis.
5. Conclusions
Patients with IBD had a significantly higher risk of developing PD compared to non-IBD
individuals, regardless of health care use. Therefore, patients with IBD should be aware of the potential
risks for comorbid PD. Corticosteroid and anti-TNF use may prevent the occurrence of PD in patients
with IBD.
Supplementary Materials: The following are available online at http://www.mdpi.com/2077-0383/8/8/1191/s1,
Table S1: Risk of Parkinson’s disease among patients with inflammatory bowel diseases in a literature review,
Table S2: Incidence and risk of Parkinson’s disease in patients with inflammatory bowel disease aged less than 60
years, Table S3: Incidence and risk of Parkinson’s disease in patients with inflammatory bowel disease aged 60
years and more.
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